Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

California’s Gate Bioscience, a biotech developing molecular gates, a new class of small molecule drugs to eliminate ...

Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Port Angeles’ Day of Play, music and stage performances highlight weekend events on the North Olympic Peninsula.

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...